痛泻要方治疗腹泻型肠易激综合征研究进展

Research Progress on the Treatment of Diarrhea Type Irritable Bowel Syndrome with Tongxie Yaofang

肠易激综合征伴腹泻(IBS-D)是一种常见的慢性功能性胃肠道疾病,在世界范围具有较高发病率,具有病程长、易复发等特点,严重时会对人的心理和身体造成很大影响。痛泻要方作为治疗IBS-D的中医经典方剂,有补脾柔肝、祛湿止泻之效。现代实验研究表明,痛泻要方及其配伍成分可通过抑制PAR-2受体的表达、抑制NF-κB信号通路、调节内脏过敏大鼠miRNA表达、降低结肠5-HT水平、调节c-Fos表达、上调OCLN和ZO1表达等多靶点多途径改善肠道通透性、内脏敏感性,抑制炎症反应从而缓解IBS-D的一系列症状。临床研究亦证实痛泻要方对于治疗IBS-D具有较好的疗效及安全性。对痛泻要方治疗IBS实验研究及临床研究的相关文献进行整理与总结,探讨该方治疗IBS-D的作用机制及临床疗效,以期为日后该病的治疗提供准确、系统的科学依据,为临床用药提供参考。

Irritable Bowel Syndrome with diarrhea(IBS-D)is a common chronic functional gastrointestinal disease,which has a high incidence rate worldwide.It has a long course of disease,easy to relapse and other characteristics,and will have a greater impact on people's psychology and body in serious cases.As a classic formula for treating IBS-D in traditional Chinese medicine,Tongxie Yaofang has the effects of tonifying the spleen,softening the liver,dispelling dampness,and stopping diarrhea.Modern experimental studies have shown that the painful diarrheal prescription and its compatibility components can improve intestinal permeability,visceral sensitivity,and inhibiting inflammation by inhibiting PAR-2 receptor expression,inhibiting NF-κB signaling pathway,regulating c-Fos expression and ZO 1 expression,which can alleviate a series of symptoms of IBS-D.Clinical studies also confirmed that it have good efficacy and safety for the treatment of IBS-D.Now the experimental research and clinical studies of IBS are summarized to explore the mechanism and clinical efficacy of IBS-D.In order to provide an accurate and systematic scientific basis for the treatment of this disease in the future,and to provide a reference for clinical drug use.